Clinical Pharmacology - Biomolecular - Modeling and Simulation

(W0930-11-61) Setting up Success in the Clinic through Semi-mechanistic Translational Modelling

(M0930-11-62) Efficacy Difference of Antipsychotics in Alzheimer's Disease and Schizophrenia: Explained with Network Efficiency and Pathway Analysis Methods

(T0930-11-62) Exploration of Predictive Bioequivalence: Comparison of Methods to Incorporate In Vitro Dissolution Data in Pharmacokinetic Modeling of BCS Class II Acidic Drugs

(T1130-11-61) A Computational Semi-mechanistic Pharmacology Model of ATG101, a PD-L1/4-1BB Bispecific Antibody for Treatment of Solid Tumors

(M1330-11-62) ILDsym^®, a Quantitative Systems Pharmacology (QSP) Platform, Successfully Simulates the Pathophysiology of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD) and Inter-patient Variability

(M1530-11-62) Mathematical Modeling to Optimize Dosing Schedules for COVID-19 Vaccines

(T1530-11-63) A Platform for Mechanistic Modelling of Subcutaneous Administration with the Effect of Immunogenicity within the Open Systems Pharmacology Framework

(M1530-11-63) A Population Pharmacokinetic Modeling Approach in Determining the Absolute Bioavailability of Sibeprenlimab, an IgG2 Monoclonal Antibody, from Two Single Ascending Dose Trials in Healthy Subjects

(M1530-11-64) Use of Quantitative Systems Toxicology (QST) to Identify Potential Intrinsic Mechanisms of Toxicity

(M1530-11-65) Population Pharmacokinetic Modeling of Encapsulated Dexamethasone Sodium Phosphate in Autologous Erythrocyte (EryDex system) in the Treatment of Ataxia Telangiectasia